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ABSTRACT 
 
 
ROLE OF ETHANOL AS A COFACTOR IN HAART INDUCED 
HEPATIC STEATOSIS AND INJURY 
 
Hridgandh Donde 
 
March 29, 2013 
 
 
Highly Active Antiretroviral Therapy (HAART) has led to a significant 
increase in the life expectancy of HIV patients; however, there are significant side 
effects including lipodystrophy and hepatotoxicity. Alcohol abuse is highly 
prevalent in HIV infected individuals and hence may be a significant negative 
cofactor in HAART induced hepatotoxicity. The present study examines the 
mechanisms underlying HAART and alcohol induced hepatotoxicity. The effects 
of HAART drugs (azidothymidine, and Indinavir sulphate) in combination with 
alcohol were examined in in vivo animal model.  
Alcohol and HAART drug interactions and hepatotoxicity were also 
assessed in-vivo using an animal model of chronic alcohol feeding.  Mice were 
pair-fed liquid diets (Lieber DeCarli) containing 35% of calories as alcohol 
(alcohol-fed, AF) or as isocaloric maltose-dextrin (pair-fed, PF) for four weeks. In 
 v 
addition, HAART treatment groups received AZT (30mg/kg BW) and IDV 
(50mg/kg BW) by oral gavage for 2 weeks.  Animals exposed to both alcohol and 
HAART developed increased visceral adiposity compared to pair-fed animal 
suggesting disturbances in lipid metabolism in these mice. Lipodystrophy was 
also evidenced by macro and microvesicular steatosis in the livers; elevated liver 
triglycerides and free fatty acids. Additionally, animals receiving combinations of 
alcohol and HAART exhibited increased inflammation and greater hepatic 
neutrophil infiltration.  
Overall, our data demonstrate that alcohol exacerbates HAART hepatotoxicity, 
and is a significant cofactor in the development of hepatic steatosis and liver 
injury.
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INTRODUCTION 
 
HIV/AIDS- An overview 
 
HIV (Human Immunodeficiency Virus) infection is one of the world's leading 
infectious diseases, claiming more than 25 million lives over the past three 
decades. HIV infection is considered pandemic by the World Health Organization 
(WHO). Thirty four million people are affected worldwide. Center for Disease 
Control (CDC) estimates 1.2 million people in the United States (US) are living 
with HIV infection. One in five (20%) of those people are unaware of their 
infection. By race, African Americans face the most severe HIV burden. Men 
having sex with men (MSM), particularly the young, are most severely affected. 
HIV leads to AIDS (Acquired Immunodeficiency Syndrome). AIDS was first 
recognized in the United States in the summer of 1981, when the U.S. (CDC) 
reported the unexplained occurrence of Pneumocystis jiroveci (formerly P. carinii) 
pneumonia in five previously healthy homosexual men in Los Angeles [1].In 
1983, human immunodeficiency virus (HIV) was isolated from a patient with 
lymphadenopathy, and by 1984 it was demonstrated clearly to be the causative 
agent of AIDS [1]. Since the epidemic began, an estimated 1,108,611 people in 
the US have been diagnosed with AIDS [1]   
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HIV & HAART  
In order to prevent or delay resistance development, physicians are using a 
regimen which consists of a combination of several types of antiretroviral drugs 
that act on different sites on a retro virus and also target different stages in the 
lifecycle of the virus. Such treatments are called highly active antiretroviral 
therapy (HAART) [2] . The development of multi-drug combination therapy for 
treatment of HIV disease is considered one of the great success stories of 
modern medicine. In a period of approximately ten years, the death rate from HIV 
disease was reduced by 50 to 80% [3]. Highly Active Antiretroviral Therapy 
(HAART) as treatment for HIV infection has greatly improved mortality and 
morbidity for adults and children living with HIV around the world [4, 5]. HAART is 
the only treatment available to suppress the viral load. Currently used HAART 
medication include Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
(Zidovudine, Didanosine, Abacavir), Non-nucleoside Reverse Transcriptase 
Inhibitors (NNRT) (Nevirapine, Etravirine), Protease inhibitors (PI) (Indinavir or 
IDV, Ritonavir, Lopinavir, Atazanavir), Fusion inhibitors (Enfuvirtide), Integrase 
Inhibitors (Raltegravir), and CCR5 inhibitors all of which act on different sites on 
HIV facilitating a decrease in viral load. Since the introduction of highly active 
antiretroviral therapy (HAART) in the mid-1990s, the life expectancy of patients 
with HIV has increased significantly [6, 7]. Although HAART has been widely 
used in the treatment of HIV, HIV infected patients have experienced 
complications associated with HAART, which cannot be ignored. Antiretroviral 
toxicity, resistance, and adherence rank high on the list of problems that must be 
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overcome if all, or at least the vast majorities, of HIV-infected patients are to gain 
the long-term benefits associated with HAART [8]. Among these problems, 
toxicity, real or perceived, is a major reason for patients either refusing or 
prematurely discontinuing HAART [9].  
 
The drop in mortality and morbidity due to opportunistic infection has been 
accompanied by a concomitant increase in HAART-related hepatotoxicity which 
caused discontinuation of HAART in increasing numbers of patients. HAART 
hepatotoxicity, including lactic acidosis, hepatic steatosis and lipodystrophy, 
occurs in approximately 10% of patients and is higher in those with underlying 
liver disease [10].  
 
Nucleoside Reverse Transcriptase Inhibotors (NRTI)- Nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs), which inhibit the formation of viral DNA 
by incorporating into the newly formed DNA molecules, thereby preventing 
further elongation of those molecules [2].  
Zidovudine (AZT) - an important drug for 1st line therapy of HAART: 
Zidovudine (AZT) (3'-azido-2'3'-dideoxythymidine) an analogue of thymidine, was 
first discovered by Mitsuya and associates' to have antiretroviral activity. In 1986, 
FDA approved this drug for the treatment of advanced HIV infection. Even today 
it is widely being used in the resource limited settings as one of the important 
drug for the 1st line therapy of HAART. However, it is now accepted that 
prolonged use AZT leads to hepatotoxicity [11-13]. Mechanisms of hepatotoxicity 
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induced AZT involves hepatomegaly or steatosis [14], elevated blood lactate to 
pyruvate ratios, cytochrome c deficiency [11, 15-17]. Additionally, elevated liver 
enzymes (AST, ALT) have been reported in patients receiving AZT therapy.  
These hepatotoxic consequences are related only to AZT administration and are 
independent of AIDS disease progression. This was confirmed when patients 
administered with AZT therapy experienced one or more of these hepatotoxic 
effects but when the therapy was discontinued the adverse effects were resolved 
[18, 19]. These toxicities are mostly mediated through mitochondrial damage and 
are associated with mitochondrial DNA depletion [17, 20]. Additional work is 
required to identify molecular mechanisms to obtain a better understanding of 
HAART/AZT induced hepatotoxicity and to develop therapeutic strategies. Hence 
in the present study, we investigate the occurrence and mechanisms involved in 
Zidovudine (AZT) induced hepatotoxicity in vivo in our well-established animal 
model. 
 
Protease Inhibitor (PI) - Protease inhibitors block the activity of the protease 
enzyme, which HIV uses to degrade large polyproteins into the smaller pieces 
required for assembly of new viral particles. All PIs are metabolized in the liver by 
CYP3A isoenzymes; consequently their metabolic rates may be altered in the 
presence of CYP inducers or inhibitors. Hence co-administration of PIs with 
ritonavir (RTV), a potent CYP3A inhibitor will optimally increase PI exposure. Co-
administration of PIs with a potent CYP3A inducer may lead to suboptimal drug 
concentrations and reduced therapeutic effects of the PI [21]. While HIV can still 
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replicate in the presence of protease inhibitors, the resulting virions are immature 
and unable to infect new cells. PI –based regimen has seen demonstrated to 
have anti-virologic potency. Unlike NRTI resistance, virologic failure rarely 
selects for PI-resistance, which confers it with increased efficiency in decreasing 
the viral load.  
 
Indivavir- A commonly used Protease inhibitor in resource limited setting:  
In 1996 Indinavir was approved as one of the PIs by the FDA, which dramatically 
modified the clinical management of HIV-1. IDV is a synthetic peptidomimetic 
competitive inhibitor of the HIV aspartyl protease, which is involved in the 
cleavage of the gag and pol gene products into their functional components and, 
as a consequence, viral particles are unable to undergo final maturation into 
infectious virions. A number of metabolic abnormalities, including 
hypertriglyceridemia, hypercholesterolemia, hyperinsulinaemia and lipodystrophy 
increase in liver enzymes have been associated with PI use [21-23]. Thus along 
with the efficacious nature of PI based therapy, recent studies have revealed 
several adverse effects leading to discontinuation of the therapy causing the viral 
load to increase. Hence this demands a need to investigate the underlying 
molecular mechanisms that could provide potential therapeutic interventions.  
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 HAART associated hepatotoxicity and liver injury 
HAART causes a variety of adverse effects like cardiovascular diseases, 
neurological disorders, Liver disease, lipodystrophy, non-Hodgkin lymphoma to 
name a few. Liver disease is recognized as an increasingly important problem for 
the HIV population, and may be due to a variety of factors including co-infection 
with viral hepatitis, alcohol abuse, and antiretroviral hepatotoxicity. Liver disease 
is now a leading cause of death for patients with HIV. In patients co-
infected with HIV and hepatitis C, cirrhosis was the underlying cause of 
death in nearly 50% [9]. In a more general HIV population, liver disease was 
the second most common non-HIV-related cause of death, trailing only 
cancer [24]. In a recent American study, which evaluated the causes of death of 
HIV-infected individuals, discontinuation of ART due to hepatotoxicity increased 
from 6% in 1996 to 31.8% in 1998-1999 among those mortalities [25]. The 
severity of liver toxicity ranges from the absence of symptoms to liver 
decompensation, and the reported incidence of severe liver toxicity after initiating 
HAART ranges from 2% to 18%. Hepatotoxicity due to HAART is also common 
and up to 30% of patients on HAART experience World Health Organization 
grade 3 liver enzyme elevations. Hepatotoxicity induced by these agents has 
been identified on the basis of circulating liver enzymes (ALT, AST, and GGT) in 
association with increased lactate levels. In more dramatic situations, liver failure 
has occurred leading to discontinuation of treatment. The study of hepatotoxicity 
induced by HAART is complicated by the diverse chemical nature of the agents 
and by the differences between the effects of agents used singly or in 
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combination. Hepatotoxicity from antiretroviral drugs has led to adverse patient 
outcomes either from fulminant hepatic failure, or more commonly, AIDS 
following discontinuation of HAART. Hence, it is highly relevant to study the 
underlying mechanisms of HAART-induced hepatotoxicity.  
HAAART-induced dyslipidemia and liver lipid metabolism 
It has been recently found in long-term and short-term studies that on healthy as 
well as HIV infected patients, HAART regimen particularly protease inhibitors 
induces dyslipidemia [23, 26-28]. Often Clinicians supplement these drugs with 
lipid lowering drugs.  
 Since liver is the first organ to come in contact with the administered 
HAART, liver is the key organ in handling multiple downstream processes and 
their metabolites. Hepatocytes are involved in lipid homeostasis and the 
metabolism of drugs. Endoplasmic reticulum (ER) plays a key role in regulating 
hepatic lipid metabolism. The ER is a critical organelle responsible for proper 
protein folding, cellular calcium levels, lipid synthesis and the secretory pathway. 
Thus ER stress is induced via depletion of ER calcium stores, changes in ER 
lipid membrane composition or accumulation of misfolded protein. 
 Moreover, sterol regulatory element-binding proteins (SREBPs) are 
transcription factors that are present on ER membrane. The isoforms of SPEBP  
(SREBP-1c and SREBP-2) play a major role in regulating the expression of key 
genes such as 3-hydroxy-3-methlgutaryl-CoA (HMG-CoA) synthase, Fatty acid 
synthase (FAS), acetyl-CoA carboxylase (ACC) involved in lipid metabolism. ER 
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stress via altering lipid metabolism could be a potential mechanism of PI-induced 
dyslipidemia and deregulation of hepatic lipid metabolism. 
Alcohol as a cofactor in HAART (AZT and IDV) induced Hepatotoxicity 
As per National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC) an estimated 136 million adults consume alcohol in the United States, 
and an estimated 14 million Americans are alcoholics[29]. Alcoholic liver disease 
accounts for 40% of deaths due to cirrhosis and more than 30% of hepatocellular 
carcinoma. Alcohol abuse and HIV are important health problems. Alcohol use is 
common in the HIV population. It is estimated that approximately 25% of recently 
diagnosed HIV patients also developed alcohol addiction, which has been 
associated with HIV treatment failure [30]. Studies have shown that alcohol 
abuse is associated with more severe hepatotoxicity in patients on HAART [31]. 
Importantly, alcoholic liver disease and HAART induced liver injury share many 
potential mechanisms of injury. These include cytokine dysregulation, 
mitochondrial dysfunction, and proteasomal dysfunction. Through these and 
other mechanisms, alcohol and antiretroviral medications converge on the liver in 
an overlapping fashion to produce hepatotoxicity. Alcohol abuse can cause a 
variety of metabolic abnormalities including induction of CYP2E1, mitochondrial 
dysfunction, oxidative stress, depressed hepatic proteasome function, hepatic 
steatosis, and in some instances more advanced liver disease with chronic 
abuse [32-34]. Alcohol abuse also can increase susceptibility to certain types of 
drug-induced liver injury (e.g., acetaminophen) and accelerate the progression of 
chronic liver disease such as HCV [8, 33, 35].  Additionally, Zidovudine and 
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indinavir as mentioned previously has been reported to develop severe hepatic 
steatosis, elevated liver enzymes and hepatotoxicity. Since alcohol and HAART 
drugs (AZT, IDV) have similar hepatotoxic effects on liver, we propose that the 
combination would exacerbate these effects. Hence in this study we are studying 
the combinatorial effects of alcohol and HAART (AZT, IDV) on liver that would 
pinpoint some therapeutic interventions. Besides liver, alcohol abuse also has an 
adverse impact on other organ systems particularly the gut, liver and the immune 
system. Work done by our research group and others has shown that chronic 
alcohol exposure leads to intestinal oxidative stress, epithelial barrier disruption 
and enhancement of gut leakiness and consequent endotoxemia and systemic 
inflammatory response [36].  
Gut-Derived Endotoxemia and Alcohol-induced liver injury: 
Due to its anatomical links to the gut, the liver is constantly exposed to gut-
derived bacterial products, and functions as a major filter organ and a first line of 
defense. Gut-derived endotoxin is a crucial mediator of liver injury in alcoholic 
liver disease. This is demonstrated by the significant reduction of alcoholic liver 
injury following elimination of the Gram-negative microbiota by antibiotics [37] 
and the sensitization to LPS-induced liver injury following long-term ethanol 
exposure [38]. The elevation of endotoxin appears to be predominantly caused 
by two mechanisms. First, alcohol consumption leads to changes in the intestinal 
microbiota; and upper gastrointestinal tract bacterial overgrowth is more than six 
times more frequent in people who are very heavy drinkers than in people who 
do not drink heavily [39, 40]. However, the effects of alcohol on the composition 
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of the intestinal microbiota have not been studied in detail. Second, a large body 
of literature has clearly documented that alcohol ingestion disrupts the intestinal 
epithelial barrier causing enhanced permeability [41-43] thus allowing increased 
amounts of LPS to enter the portal circulation. Moreover, it has been suggested 
that the intestinal microbiota converts ethanol into acetaldehyde, which in turn 
disrupts tight junctions and increases paracellular permeability [44, 45]. On the 
other hand, not much is known about the effects of HAART drugs per se on 
systemic endotoxin or Lipopolysaccharide (LPS). Most of the clinical trial studies 
focus on HIV-1 infection and the increase systemic endotoxin. Hence more 
studies are required to tease out the effects of HAART on endotoxin levels and 
its subsequent hepatic consequences. In order to address this issue we are 
interested in finding the effects of HAART on systemic endotoxin in vivo.  
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SIGNIFICANCE AND CLINICAL RELEVANCE 
In the United States, approximately 2000 cases of acute liver failure occur 
annually and drugs account for over 50% of them (39% are due to 
acetaminophen, 13% are idiosyncratic reactions due to other medications). 
Drugs account for 2-5% of cases of patients hospitalized with jaundice and 
approximately 10% of all cases of acute hepatitis. HAART has been associated 
with increase in morbidity and mortality due to HAART-related hepatotoxicity and 
finally discontinuation of therapy. This is especially true in patients who are co-
infected or have other cofactors such as alcohol abuse. The mechanisms for 
HAART hepatotoxicity in association with alcohol consumption or other cofactors 
have received very limited attention. There is no well-accepted therapeutic 
intervention except for abstinence and HAART discontinuation. Recent work 
indicates that the liver is an important target for alcohol-induced damage and is 
often associated with gut-generated signals. Findings from this project could 
provide important mechanisms by which alcohol/HAART-induced pathology in 
the gut influences the liver inflammatory responses often observed in alcohol 
abuse. Moreover, the findings from this study would be significant in the 
development of successful preventive and therapeutic strategies in most-at-risk 
populations. Finally, the proposed studies will focus on direct hepatotoxicity due 
to HAART and alcohol as a co-factor by the combinations of Zidovudine and 
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Indinavir (HAART drugs), defining the disease mechanisms and generate 
therapeutic targets.  
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MATERIALS AND METHODS 
Reagents  
Zidovudine (AZT) and Indinavir (IDV) were purchased from Sigma-Aldrich (St. 
Louis, MO). Chloroacetate Esterase Staining reagents were also obtained from 
Sigma-Aldrich (St. Louis, MO). TRIzol® was obtained from Invitrogen (Carlsbad, 
CA). Triglycerides and ALT (Alanine Aminotransferase) reagents were obtained 
from Thermo Fisher Scientific Inc.  Reagents for Free Fatty acids were obtained 
from Wako Chemical USA (Richmond, VA, USA); Endotoxin reagents were 
obtained from with Limulus Amebocyte Lysate kit (Lonza, Walkersville, MD).  
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 Animal Model 
Eight-week-old male C57BL⁄6N mice were obtained from Harlan (Indianapolis, 
IN). All mice were housed in a pathogen-free, temperature-controlled animal 
facility accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care with 12- hour light ⁄ 12 hour dark cycles. All experiments 
were carried out according to the criteria outlined in the Guide for Care and Use 
of Laboratory Animals and with approval of the University of Louisville Animal 
Care and Use Committee. 
Animals were fed a modified Lieber–DeCarli liquid diet containing Ethanol (EtOH) 
(35% of total calories) and enriched in Unsaturated Fatty Acid (USF) (corn oil); 
Research Diet, New Brunswick, NJ.  Control liquid maltose-dextrin diets provided 
40% of energy from fat, 43% from carbohydrate, and 17% from protein. Initially, 
all mice were given the control liquid maltose dextrin diets (USF, no EtOH) ad 
libitum for 1 week. Afterward, mice were fed either the liquid EtOH diet or the 
control liquid maltose-dextrin diet. EtOH was gradually increased every 3 to 4 
days from 11.2 to 35% of total calories [(5.0%(v⁄v)]. The mice were fed the 
Ethanol diet [5% (v⁄v)] ad libitum for 4 weeks. The control mice were pair-fed USF 
maltose-dextrin diets on an isocaloric basis. For HAART therapy, (AZT 30mg/kg) 
and (IDV 50mg/kg) were gavaged every day for last 2 weeks to animals 
administered alcohol or pair-fed (control) diet. 
At the end of the feeding experiment, mice were anesthetized with sodium-
pentobarbital (nembutal, 80 mg ⁄ kg, intraperitonially), and blood and liver were 
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collected for assays. The killing sequence was randomized to eliminate any time-
dependent variation due to length of fasting. Blood samples were collected from 
the inferior vena cava using heparinized syringes and were then centrifuged at 
7000·g for 7 minutes at 4°C. Whole liver were removed. Part of the liver from left 
lobe was harvested and fixed in 10% neutral- buffered formalin, while the 
remaining liver tissue was snap frozen in liquid N2 and stored at 80°C.  
Hematoxin and Eosin staining 
Staining was performed using Hemo-De or Citrosol. Staining was done in a 
Copland jar with a stir bar at the bottom of the jar. All slides should be stained 
with hematoxylin and eosin, respectively. Consequently the slides were kept in 
Hemo-De for 10mins, 100% EtOH for 10mins, 95% EtOH for 10mins, 85% EtOH 
for 10mins, 70% EtOH for 10mins and 30% Etoh for 10mins followed by 
Hematoxylin soln for 1-3mins. 
Liver Histological Examination 
For histological analysis, liver sections were fixed in 10% buffered formalin for 24 
hours and embedded in paraffin. Tissue sections were stained with hematoxylin-
eosin and examined under light microscopy at 200· magnification. 
Oil Red O staining 
Frozen liver sections were washed in phosphate buffered saline twice for 5 
minutes. Oil-Red-O and 85% propylene glycol were added with agitation for 15 
minutes, followed by washing in tap water. 
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Chloroacetate Esterase Stain 
Neutrophil accumulation was assessed by localizing chloracetate esterase 
(CAE), a specific marker for neutrophils, in liver tissue by using the naphthol AS-
D chloracetate esterase kit (Sigma) 
ALT assay 
Alanine aminotransferase (ALT) activity was measured as a marker of liver injury 
using commercially available reagents from Thermo Fisher Scientific Inc. 
(Middletown, VA). 
Liver Triglycerides Assay 
For liver TAG assay, hepatic tissue (100 mg) was homogenized in 50 mM NaCl. 
The homogenate (500 μl) was mixed with chloroform/methanol (2:1, 4 ml) and 
incubated overnight at room temperature with gentle shaking. Homogenates 
were vortexed and centrifuged for 5 min at 3000Å~g. The lower lipid phase was 
collected and concentrated by vacuum. The lipid pellets were dissolved in 1% 
Triton X100 in phosphate-buffered saline, and hepatic TAG content was 
determined via enzymatic colorimetric methods. 
Hepatic Free Fatty Acids 
Liver nonesterified-fatty acid (NEFA) were assayed using a commercially 
available kit fromWako Chemical USA (Richmond,VA). 
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Blood Endotoxin Assay 
Plasma endotoxin levels were measured with Limulus Amebocyte Lysate kit 
(Lonza, Walkersville, MD) according to the manufacturer’s instructions. 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 5.01 for 
Windows (GraphPad Software, Inc., La Jolla, CA). One-way analysis of variance 
(ANOVA) followed by Tukey’s post hoc test was used to evaluate significant 
differences between the 4 compared groups (Pair-Fed Controls+ EtOH, HAART 
drugs, EtOH+HAART drugs). A p-value of <0.05 was considered statistically 
significant. Data were expressed as mean ± SEM. 
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RESULTS 
 
HAART drugs in combination with alcohol increases visceral fat 
accumulation in mice in comparison with HAART or alcohol-fed groups 
Lipodystrophy is one of the common features of long-term HAART therapy 
commonly seen in HIV-1 infected patients. This is associated with a loss in 
peripheral fat and an increase in visceral fat accumulation [46, 47]. However, 
whether alcohol consumption along with HAART drugs would further enhance 
HAART induced lipodystrophy still remains unclear. Hence, we visually examined 
the visceral fat accumulation in our experimental groups. Our data suggests that 
the combination group (Alcohol+HAART) had a significant amount of visceral fat 
accumulation in comparison with the mice gavaged HAART drugs and/or alcohol-
fed groups showing an additive effect of drugs and alcohol. This could be possibly 
due to decrease in the amount of lipolysis in the adipocytes as well as in the 
hepatocytes or increased lipogenesis in mice receiving HAART and alcohol (fig. 
1). 
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Figure 1: Administration of HAART drugs and alcohol leads to increased 
visceral fat accumulation 
Pictorial representation of mice from different groups such as HAART drugs and 
alcohol (alcohol+ AZT+IDV), HAART drugs (AZT+IDV), alcohol and pair-fed 
(controls) showing visceral fat accumulation the most in HAART drugs and 
alcohol group (alcohol+ AZT+IDV) 
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Administration of HAART drugs and alcohol enhances alcohol induced           
Micro- and Macro-Vesicular Steatosis 
Since we reported increased visceral fat accumulation in (alcohol+AZT+IDV) 
group (fig. 1) we were interested in examining the fat deposition (steatosis) in the 
whole liver. We examined the effect of HAART and alcohol on the whole liver by 
Hematoxylin and Eosin (H&E) staining and Oil Red O staining. Alcohol further 
worsened HAART induced steatosis. Indeed, we confirm the development of 
both micro- and macro vesicular steatosis in (alcohol+AZT+IDV) group (fig. 2). 
This data suggests that HAART drugs in combination with Alcohol could 
potentially exacerbate hepatic steatosis in comparison with HAART drugs or 
alcohol administered mice.  
 
 
 
 
 
 
 
 
 
 21 
 
Figure 2: H&E staining of liver tissue 
H&E staining of hepatic sections established the presence of micro-vesicular 
steatosis in alcohol and the (Alcohol+AZT+IDV) fed groups. 
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Figure 3: Oil Red O Staining of liver tissue 
Oil Red O staining of hepatic sections established the presence of macro-
vesicular steatosis in alcohol and the (Alcohol+AZT+IDV) fed groups. 
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Administration of HAART drugs and alcohol significantly increases hepatic 
triglycerides whereas hepatic free Fatty acids levels remained unchanged 
in (alcohol+AZT+IDV) and AZT+IDV groups in comparision with alcohol and 
controls group 
In the liver, glycerol combines with fatty acids to form triglycerides as a byproduct 
of digestion of fats. Triglycerides play a very important role in digestion and 
metabolism by acting as transporters of dietary fats. The presence of fatty livers 
results mainly from the accumulation of triacylglycerols. Moreover free fatty acids 
are a key mediator of lipotoxicity in the liver. Increase in triglycerides and free 
fatty acids in the liver could potentially lead to lipodystrophy and dyslipidemia. 
Hepatic fat accumulation (fig.2, 3) was further confirmed by increase in the 
hepatic triglycerides. Hepatic triglycerides and free fatty acids were quantified 
biochemically. 
In (AZT+IDV) group hepatic triglycerides were significantly higher than pair-fed 
(controls). Additionally, hepatic triglycerides in (alcohol+AZT+IDV) were 
significantly high than (AZT+IDV) or control groups. On the contrary, there was 
no significant difference in the free fatty acids in the above mentioned groups.  
 
 
 
 
 24 
 
Figure 4: Effects of HAART (AZT+IDV) and alcohol singly and in 
combination on hepatic triglycerides and free fatty acids (FFA) 
Hepatic triglycerides were quantified as (mg/g liver) in mice whereas Free fatty 
acids (FFA) was measured in (mEq/L) in mice fed with alcohol, (AZT+IDV), 
(Alcohol+AZT+IDV) and pair-fed (control). (Alcohol+AZT+IDV) significantly 
increased hepatic triglyceride levels compared to pair-fed (control), (AZT+IDV) 
whereas FFA levels remained unchanged. Data is presented as mean ± SEM, 
n=5 animals/group; * p<0.05 when compared to controls. Anova was used to 
evaluate significant differences between the 4 different groups 
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Administration of HAART drugs and alcohol causes increased serum 
endotoxin levels in mice. 
Work done by our research group and others has shown that chronic alcohol 
exposure leads to intestinal oxidative stress, epithelial barrier disruption and 
enhancement of gut leakiness and consequent endotoxemia and systemic 
inflammatory response [36]. Acute and chronic ingestion of alcohol lead to a 
significant elevation of portal and systemic levels of endotoxin in animal models 
and humans[48-50]. In our experimental groups we reported significantly higher 
serum endotoxin levels specifically in (alcohol+AZT+IDV) fed mice as compared 
to (AZT+IDV) and pair-fed (control) groups (fig. 5).   
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Figure 5: Effects of HAART drugs (AZT+IDV) and alcohol singly and in 
combination on serum endotoxin 
Serum endotoxin levels were quantified as (EU/ml) in mice fed with alcohol, 
(AZT+IDV), (Alcohol+AZT+IDV) and pair-fed (control). (Alcohol+AZT+IDV) 
significantly increased systemic endotoxin levels as compared to (AZT+IDV) and 
pair-fed(control). Data is presented as mean ± SEM, n=5 animals/group;              
* p<0.05.  
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Administration of HAART drugs and alcohol leads to an increase in 
neutrophil infiltration (Inflammation) 
 
Neutrophils accumulate within the hepatic microvasculature, which 
includes sinusoids and in postsinusoidal venules. A variety of inflammatory 
mediators such as TNF-α, IL-1, CXC chemokines [(e.g., IL-8, Macrophage 
inflammatory protein-2 (MIP-2), keratinocyte-derived chemokine (KC), cytokine-
induced neutrophil chemoattractant-1 (CINC-1)], and platelet activating factor 
(PAF)), can cause neutrophil infiltration within the hepatocytes [51-55]. It is well 
known that alcohol consumption in humans results in neutrophilic steatohepatitis  
[56-58]. Neutrophil infiltration in the liver is known to significantly contribute to the 
pathologic findings noted in alcoholic liver injury (ALI) [56, 57, 59].  
In order to evaluate the Neutrophils accumulation we performed 
Chloroacetate Esterase (C&E) Staining procedure in the whole liver. We 
confirmed increased levels of neutrophils in HAART and alcohol administered 
mice livers as compared to individual groups.  
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Figure 6: CAE staining of liver tissue 
CAE staining of hepatic sections established the presence of neutrophil 
recruitment in (Alcohol+AZT+IDV) mice group 
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Administration of HAART drugs and alcohol lead to an increase in serum 
ALT levels 
Serum alanine aminotransferase (ALT) levels are the hallmark of liver injury. It 
has been well documented that chronic alcohol consumption leads to elevated 
ALT levels in the blood indicating liver injury. In the present study, ALT levels 
were significantly elevated in Alcohol and in (alcohol+AZT+IDV) groups in 
comparison with pair-fed (Control). Although, ALT levels in (alcohol+AZT+IDV) 
were not significantly higher than alcohol group.  
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Figure 7: Effects of HAART (AZT+IDV) and alcohol on serum ALT levels 
Serum ALT levels (U/L) were measured using ALT reagent from Thermo 
Scientific as per manufacturer’s instructions. Chronic alcohol & HAART 
(alcohol+AZT+IDV) administration resulted in significant increase in the serum 
ALT levels in comparison with pair-fed (control) , and AZT+IDV fed mice. Data is 
presented as mean ± SEM, n=5 animals/group; * p<0.05. Anova was used to 
evaluate significant differences between the above mentioned groups. 
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DISCUSSION 
In this study, we tested the combinatorial the effects of HIV medication 
HAART specifically a combination of NRTI and PI with chronic alcohol 
consumption on hepatic injury in animals. Chronic alcohol consumption (4 
weeks) lead to a fulminant steatohepatitis and moderate dyslipidemia that is 
consistent with other well documented studies. Administration of HAART drugs 
further increased the hepatotoxic consequence of alcohol.  
In our results, combination of HAART and alcohol resulted in a synergistic 
increase in visceral fat accumulation already seen in the group of animals on 
HAART drugs. It is well-documented that visceral-fat accumulation is associated 
with the use of PIs like Indinavir [60]. This data clearly suggests that there is a 
possibility of dysregulation in the body fat redistribution and potential 
lipodystrophy in animals receiving HAART and alcohol. Consequently, we 
confirmed that micro- and macro- vesicular steatosis was significantly increased 
in animals receiving HAART and alcohol as compared animals administered 
HAART or alcohol alone. This further established the occurrence of dyslipidemia 
in these animals.  
It has been shown in humans as well as animals that chronic alcohol 
consumption leads to the development of fatty liver [61].  This incidence of fatty 
liver is due to the accumulation of triacylglycerols. Since we confirmed the 
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occurrence of macro- and micro- vesicular steatosis in the whole livers of these 
mice we analyzed the lipid profile specifically hepatic triglycerides and free fatty 
acids. As expected, we reported marked increase in the hepatic triglycerides in 
animals receiving alcohol as well as HAART in comparison with HAART or 
alcohol and pair-fed controls. 
Work done by our research group and others has shown that chronic 
alcohol exposure leads to intestinal oxidative stress, epithelial barrier disruption 
and enhancement of gut leakiness and consequent endotoxemia and systemic 
inflammatory response. Moreover, alcohol consumption affects both aerobic and 
non-aerobic intestinal bacteria resulting in altered gut bacterial composition 
(dysbiosis). Additionally, alcohol induced endotoxemia is also influenced by 
depressed hepatic clearance of circulating endotoxin shown in both acute and 
chronic alcohol consumption causing intestinal barrier dysfunction. Moreover, 
there are no clinical reports or literature on the effect of HAART drugs per se 
(without any viral load) on systemic endotoxin.  In this regards, we report a 
significant increase in the circulating systemic endotoxemia in animals on 
HAART and alcohol administration when compared with HAART or alcohol group 
animals alone. Serum Aminotransferase activity, which is an indicator of liver 
injury also followed the same tread of being significantly higher in in animals 
receiving HAART and alcohol together.  
Overall, our data suggests that the combination of alcohol and HAART 
(AZT & IDV) would have detrimental on liver. Hence the mechanisms underlying 
the liver toxicity due to HAART and alcohol need further investigation which 
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would lead to potential therapeutic targets. These pharmacological interventions 
could be supplemented with HAART drugs that would help in continuation of the 
therapy without any hepatotoxic effects.  
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SUMMARY 
The highly Active Anti-Retroviral therapy has been shown to improve the life 
expectancy of HIV-1 patients during the last two decades [6, 9].  It is now clear 
that alcohol abuse can alter/suppress immune function, including CD4 T-
lymphocyte depletion, which can accelerate HIV progression. Subjects who 
consume alcohol may be more likely to develop certain infectious diseases that 
can complicate HIV, examples being various types of pneumonia and 
tuberculosis. Patients who consume alcohol also may be less compliant with their 
HIV therapy, which can affect disease progression. Moreover, Liver disease is 
now a leading cause of death for patients with HIV. Liver disease may be due to 
a variety of factors including co-infection with viral hepatitis, alcohol abuse, and 
antiretroviral hepatotoxicity. Hence in this preliminary animal study we are 
shedding some light on the mechanisms of alcohol and HAART mediated hepatic 
steatosis, inflammation and injury.  
Our data suggests that HAART medication along with a cofactor like alcohol 
causes an increase in micro- and macro-vesicular steatosis leading to an 
increase in hepatic triglycerides possibly leading to dyslipidemia. Neutrophil 
infiltration (inflammation) was clearly increased in animals receiving HAART and 
alcohol. Serum endotoxemia was significantly more in animals receiving HAART 
drugs along with alcohol indicating intestinal barrier dysfunction. We also 
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reported liver injury in the form of increased serum aminotransferase activity in 
animals on HAART and alcohol. In conclusion, alcohol/HAART combination 
causes severe hepatotoxic consequences. Further investigations are required to 
understand the underlying mechanisms leading to potential targets for 
therapeutic interventions.  
 36 
 
 
REFERENCES 
 
1. http://www.cdc.gov/hiv/resources/factsheets/us.htm. 
2. Barve, S., Moghe, A.,Kapoor, R., Ramirez, J.A., Eaton, J.W., Gobejishvili, 
L., Joshi-Barve, S.  and McClain, C.J, Alcohol Use, HIV Pharmacotherapy 
(HAART) and Liver Disease. Alcohol  Research and Health, 2010. 33: p. 
229–236. 
3. Delaney, M., History of HAART – the true story of how effective multi-drug 
therapy was developed for treatment of HIV disease. Retrovirology, 2006. 
4. d'Arminio Monforte, A., et al., Insights into the reasons for discontinuation 
of the first highly active antiretroviral therapy (HAART) regimen in a cohort 
of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of 
Antiretroviral-Naive Patients. AIDS, 2000. 14(5): p. 499-507. 
5. National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC).  3/15/08]; Available from: http://niaaa.census.gov/. 
6. Sherman, K.E., M. Peters, and M.J. Koziel, HIV and liver disease forum: 
conference proceedings. Hepatology, 2007. 45(6): p. 1566-77. 
7. Nunez, M. and V. Soriano, Hepatotoxicity of antiretrovirals: incidence, 
mechanisms and management. Drug Saf, 2005. 28(1): p. 53-66. 
 37 
8. Samet, J.H., A.Y. Walley, and C. Bridden, Illicit drugs, alcohol, and 
addiction in human immunodeficiency virus. Panminerva Med, 2007. 
49(2): p. 67-77. 
9. Bica, I., et al., Increasing mortality due to end-stage liver disease in 
patients with human immunodeficiency virus infection. Clin Infect Dis, 
2001. 32(3): p. 492-7. 
10. Johnson, A.A., et al., Toxicity of antiviral nucleoside analogs and the 
human mitochondrial DNA polymerase. J Biol Chem, 2001. 276(44): p. 
40847-57. 
11. Chariot, P., et al., Zidovudine-induced mitochondrial disorder with massive 
liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA 
depletion. J Hepatol, 1999. 30(1): p. 156-60. 
12. Deveaud, C., et al., Site specific alterations of adipose tissue mitochondria 
in 3'-azido-3'-deoxythymidine (AZT)-treated rats: an early stage in 
lipodystrophy? Biochem Pharmacol, 2005. 70(1): p. 90-101. 
13. Tanuma, J., et al., Dilated cardiomyopathy in an adult human 
immunodeficiency virus type 1-positive patient treated with a zidovudine-
containing antiretroviral regimen. Clin Infect Dis, 2003. 37(7): p. e109-11. 
14. Acosta, B.S. and E.W. Grimsley, Zidovudine-associated type B lactic 
acidosis and hepatic steatosis in an HIV-infected patient. South Med J, 
1999. 92(4): p. 421-3. 
 38 
15. Chariot, P., et al., Cytochrome c oxidase deficiency in zidovudine 
myopathy affects perifascicular muscle fibres and arterial smooth muscle 
cells. Neuropathol Appl Neurobiol, 1995. 21(6): p. 540-7. 
16. Moh, R., et al., Haematological changes in adults receiving a zidovudine-
containing HAART regimen in combination with cotrimoxazole in Cote 
d'Ivoire. Antivir Ther, 2005. 10(5): p. 615-24. 
17. Lewis, W., et al., Zidovudine induces molecular, biochemical, and 
ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest, 
1992. 89(4): p. 1354-60. 
18. Dalakas, M.C., et al., Mitochondrial myopathy caused by long-term 
zidovudine therapy. N Engl J Med, 1990. 322(16): p. 1098-105. 
19. Mhiri, C., et al., Zidovudine myopathy: a distinctive disorder associated 
with mitochondrial dysfunction. Ann Neurol, 1991. 29(6): p. 606-14. 
20. Lim, S.E. and W.C. Copeland, Differential incorporation and removal of 
antiviral deoxynucleotides by human DNA polymerase gamma. J Biol 
Chem, 2001. 276(26): p. 23616-23. 
21. 2013; Available from: http://aidsinfo.nih.gov/guidelines. 
22. Carr, A., et al., A syndrome of peripheral lipodystrophy, hyperlipidaemia 
and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 
1998. 12(7): p. F51-8. 
23. Carr, A., et al., Diagnosis, prediction, and natural course of HIV-1 
protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes 
mellitus: a cohort study. Lancet, 1999. 353(9170): p. 2093-9. 
 39 
24. Novoa, A.M., et al., Increase in the non-HIV-related deaths among AIDS 
cases in the HAART era. Curr HIV Res, 2008. 6(1): p. 77-81. 
25. Nunez, M., Hepatotoxicity of antiretrovirals: incidence, mechanisms and 
management. J Hepatol, 2006. 44(1 Suppl): p. S132-9. 
26. Pere, D., et al., Dyslipidemia and cardiovascular disease risk factor 
management in HIV-1-infected subjects treated with HAART in the 
Spanish VACH cohort. Open AIDS J, 2008. 2: p. 26-38. 
27. Periard, D., et al., Atherogenic dyslipidemia in HIV-infected individuals 
treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation, 
1999. 100(7): p. 700-5. 
28. Friis-Moller, N., et al., Class of antiretroviral drugs and the risk of 
myocardial infarction. N Engl J Med, 2007. 356(17): p. 1723-35. 
29. Bryant, K.J., Expanding research on the role of alcohol consumption and 
related risks in the prevention and treatment of HIV/AIDS. Subst Use 
Misuse, 2006. 41(10-12): p. 1465-507. 
30. Miguez, M.J., et al., HIV treatment in drug abusers: impact of alcohol use. 
Addict Biol, 2003. 8(1): p. 33-7. 
31. Price, J.C. and C.L. Thio, Liver disease in the HIV-infected individual. Clin 
Gastroenterol Hepatol, 2010. 8(12): p. 1002-12. 
32. McClain, C., et al., Dysregulated cytokine metabolism, altered hepatic 
methionine metabolism and proteasome dysfunction in alcoholic liver 
disease. Alcohol Clin Exp Res, 2005. 29(11 Suppl): p. 180S-8S. 
 40 
33. Carithers, R.I. and C.J. McClain, Alcoholic Liver Disease. Gastrointestinal 
and Liver Disease, ed. MFeldman, L. Friedman, and L. Brant. Vol. 2. 
2006, Philadelphia, PA: Elsevier. 
34. Bergheim, I., C.J. McClain, and G.E. Arteel, Treatment of alcoholic liver 
disease. Alcohol and the Gastrointestinal Tract2006, Basel, Switzerland: 
Karger AG. 
35. McClain, C.J., et al., Potentiation of acetaminophen hepatotoxicity by 
alcohol. JAMA, 1980. 244(3): p. 251-3. 
36. Kirpich, I.A., et al., The type of dietary fat modulates intestinal tight 
junction integrity, gut permeability, and hepatic toll-like receptor 
expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp 
Res, 2012. 36(5): p. 835-46. 
37. Adachi, Y., et al., Antibiotics prevent liver injury in rats following long-term 
exposure to ethanol. Gastroenterology, 1995. 108(1): p. 218-24. 
38. Hansen, J., D.L. Cherwitz, and J.I. Allen, The role of tumor necrosis factor-
alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. 
Hepatology, 1994. 20(2): p. 461-74. 
39. Bode, J.C., et al., Jejunal microflora in patients with chronic alcohol abuse. 
Hepatogastroenterology, 1984. 31(1): p. 30-4. 
40. Hauge, T., J. Persson, and D. Danielsson, Mucosal bacterial growth in the 
upper gastrointestinal tract in alcoholics (heavy drinkers). Digestion, 1997. 
58(6): p. 591-5. 
 41 
41. Worthington, B.S., L. Meserole, and J.A. Syrotuck, Effect of daily ethanol 
ingestion on intestinal permeability to macromolecules. Am J Dig Dis, 
1978. 23(1): p. 23-32. 
42. Draper, L.R., et al., Effect of alcohol on the integrity of the intestinal 
epithelium. Gut, 1983. 24(5): p. 399-404. 
43. Bjarnason, I., T.J. Peters, and R.J. Wise, The leaky gut of alcoholism: 
possible route of entry for toxic compounds. Lancet, 1984. 1(8370): p. 
179-82. 
44. Ferrier, L., et al., Impairment of the intestinal barrier by ethanol involves 
enteric microflora and mast cell activation in rodents. Am J Pathol, 2006. 
168(4): p. 1148-54. 
45. Purohit, V., et al., Alcohol, intestinal bacterial growth, intestinal 
permeability to endotoxin, and medical consequences: summary of a 
symposium. Alcohol, 2008. 42(5): p. 349-61. 
46. Babl, F.E., A.M. Regan, and S.I. Pelton, Abnormal body-fat distribution in 
HIV-1-infected children on antiretrovirals. Lancet, 1999. 353(9160): p. 
1243-4. 
47. Jaquet, D., et al., Clinical and metabolic presentation of the lipodystrophic 
syndrome in HIV-infected children. AIDS, 2000. 14(14): p. 2123-8. 
48. Fukui, H., et al., Plasma endotoxin concentrations in patients with 
alcoholic and non-alcoholic liver disease: reevaluation with an improved 
chromogenic assay. J Hepatol, 1991. 12(2): p. 162-9. 
 42 
49. Parlesak, A., et al., Increased intestinal permeability to macromolecules 
and endotoxemia in patients with chronic alcohol abuse in different stages 
of alcohol-induced liver disease. J Hepatol, 2000. 32(5): p. 742-7. 
50. Mathurin, P., et al., Exacerbation of alcoholic liver injury by enteral 
endotoxin in rats. Hepatology, 2000. 32(5): p. 1008-17. 
51. Schlayer, H.J., et al., Involvement of tumor necrosis factor in endotoxin-
triggered neutrophil adherence to sinusoidal endothelial cells of mouse 
liver and its modulation in acute phase. J Hepatol, 1988. 7(2): p. 239-49. 
52. Bautista, A.P. and J.J. Spitzer, Platelet activating factor stimulates and 
primes the liver, Kupffer cells and neutrophils to release superoxide anion. 
Free Radic Res Commun, 1992. 17(3): p. 195-209. 
53. Witthaut, R., et al., Complement and tumor necrosis factor-alpha 
contribute to Mac-1 (CD11b/CD18) up-regulation and systemic neutrophil 
activation during endotoxemia in vivo. J Leukoc Biol, 1994. 55(1): p. 105-
11. 
54. Essani, N.A., et al., Cytokine-induced upregulation of hepatic intercellular 
adhesion molecule-1 messenger RNA expression and its role in the 
pathophysiology of murine endotoxin shock and acute liver failure. 
Hepatology, 1995. 21(6): p. 1632-9. 
55. Bajt, M.L., A. Farhood, and H. Jaeschke, Effects of CXC chemokines on 
neutrophil activation and sequestration in hepatic vasculature. Am J 
Physiol Gastrointest Liver Physiol, 2001. 281(5): p. G1188-95. 
 43 
56. Bautista, A.P., Neutrophilic infiltration in alcoholic hepatitis. Alcohol, 2002. 
27(1): p. 17-21. 
57. French, S.W., Alcoholic hepatitis: inflammatory cell-mediated 
hepatocellular injury. Alcohol, 2002. 27(1): p. 43-6. 
58. Jaeschke, H., Neutrophil-mediated tissue injury in alcoholic hepatitis. 
Alcohol, 2002. 27(1): p. 23-7. 
59. Bautista, A.P., Chronic alcohol intoxication induces hepatic injury through 
enhanced macrophage inflammatory protein-2 production and intercellular 
adhesion molecule-1 expression in the liver. Hepatology, 1997. 25(2): p. 
335-42. 
60. Miller, K.D., et al., Visceral abdominal-fat accumulation associated with 
use of indinavir. Lancet, 1998. 351(9106): p. 871-5. 
61. Grant, B.F., M.C. Dufour, and T.C. Harford, Epidemiology of alcoholic liver 
disease. Semin Liver Dis, 1988. 8(1): p. 12-25.  
 44 
 
 
CURRICULUM VITAE 
 HRIDGANDH DONDE 
h.donde@louisville.edu 
(502) 554-4103 
505 S Hancock Street, CTRB room 552, Louisville KY 40202 
 
Date of Birth: December 04 1987 
Birth Place: Mumbai, India 
 
EDUCATION: 
2005 - 2008: B.S in Biochemistry University of Mumbai, India 
2008 - 2010: M.S in Biochemistry University of Mumbai, India 
2010 - Present: Graduate student in Pharmacology and Toxicology at  
              The University of Louisville, Kentucky, USA 
 
POSITION: 
2010-Present: Graduate Research Assistant (University of Louisville) 
 
AWARDS: 
IPIBS (Integrated Programs in Biomedical sciences) fellowship at University of 
Louisville. (2010-2012) 
Sponsored Research Tuition Award Fall 2012-summer 2013 at University of     
Louisville. (2012-2013) 
Invite for platform presentation and poster presentation at Research Society of 
Alcoholism (2013)  
 
 
 45 
Graduate Student Travel award for Experimental Biology (EB) 2013 
Graduate student Council travel funding (University of Louisville) for attending 
Society of Toxicology Conference (2013) 
 
PROFESSIONAL MEMBERSHIPS: 
 
2012- Present: Society of Toxicology (SOT) 
2011- Present: Ohio Valley Society of Toxicology (OVSOT) 
2011- Present: American Society for Pharmacology and Experimental 
Therapeutics (ASPET) 
 
Short Term Training and Courses:  
Certificate course at King Edward Memorial (KEM) Hospital, Mumbai for 
attending the Laboratory Services at Central Clinical Biochemistry Laboratories, 
Emergency Laboratories, Artificial Kidney Department (AKD) (May-July 2010) 
TEACHING: 
Participated in the training and supervision of summer medical student fellowship 
project: “Hepatotoxic consequences of Highly Active Anti-Retroviral Therapy 
(HAART)” 2012 
 
PUBLICATION: 
Acute exposure to acrolein, a ubiquitous environmental pollutant, and anti-
HIV Highly Active Antiretroviral Therapy (HAART) medication leads to 
hepatotoxicity. 
Smita Ghare, Hridgandh Donde, Swati Joshi-Barve, Craig McClain and Shirish 
Barve (Manuscript in preparation) 
 
 
 
 
 46 
POSTER PRESENTATION: 
Potential Role of FasL Expression and Signaling in the Induction of 
Hepatotoxicity by AZT.  
Hridgandh Donde, Smita Ghare, Wei-Yang Chen, Swati Joshi-Barve, Craig 
McClain and Shirish Barve. Research! Louisville, University of Louisville 
(2011) 
 
Ethanol is a cofactor in HAART induced hepatotoxicity 
Hridgandh Donde, S. Ghare, I Kirpich, L Gobejishvili, W Chen, S Joshi-Barve, C 
McClain and Shirish Barve. Research! Louisville, University of Louisville 
(2012) 
Ethanol is a cofactor in HAART induced hepatotoxicity 
Hridgandh Donde, S. Ghare, I Kirpich, L Gobejishvili, W Chen, S Joshi-Barve, C 
McClain and Shirish Barve. OVSOT (Ohio Valley Society of Toxicology) 
(2012) 
Ethanol is a cofactor in HAART induced hepatotoxicity 
Hridgandh Donde, S. Ghare, I Kirpich, L Gobejishvili, W Chen, S Joshi-Barve, C 
McClain and Shirish Barve. SOT (Society of Toxicology) (2013) 
INVITED PRESENTATION: 
Invite for platform presentation and poster presentation at Research Society of 
Alcoholism (2013)  
